Kovitz Investment Group Partners
ALNY icon

Kovitz Investment Group Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Kovitz Investment Group Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$648K Buy
1,958
+3
+0.2% +$1.02K 0.02% 372
2025
Q4 		$778K Sell
1,955
-652
-25% -$289K 0.02% 348
2025
Q3 		$1.19M Buy
2,607
+257
+11% +$105K ﹤0.01% 798
2025
Q2 		$766K Buy
2,350
+1
+0% +$277 ﹤0.01% 857
2025
Q1 		$634K Sell
2,349
-292
-11% -$75K ﹤0.01% 856
2024
Q4 		$622K Buy
2,641
+210
+9% +$55.2K ﹤0.01% 841
2024
Q3 		$579K Buy
+2,431
New +$633K ﹤0.01% 732

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Kovitz Investment Group Partners's ALNY Position: Q1 2026 in Review

Kovitz Investment Group Partners increased its Alnylam Pharmaceuticals (ALNY) stake by 0.15% in Q1 2026, buying an estimated $1.02K and bringing the position to 1,958 shares worth $648K. The position accounts for 0.02% of the portfolio, ranked #372.

Kovitz Investment Group Partners first reported a position in ALNY in Q3 2024 and has held it in 7 quarters since. The position peaked at $1.19M in Q3 2025. 789 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Kovitz Investment Group Partners held 1,958 shares of Alnylam Pharmaceuticals worth $648K as of Q1 2026.
  • Kovitz Investment Group Partners bought 3 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $1.02K.
  • Alnylam Pharmaceuticals made up 0.02% of Kovitz Investment Group Partners's portfolio in Q1 2026, its #372 holding.
  • Kovitz Investment Group Partners first reported a position in Alnylam Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • Kovitz Investment Group Partners's Alnylam Pharmaceuticals position peaked at $1.19M in Q3 2025.
  • 789 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Kovitz Investment Group Partners's 13F filing for Q1 2026, filed 13 May 2026.